potential therapy

Acupuncture may be a promising complementary approach for easing fatigue and improving quality of life for people with multiple sclerosis (MS), according to a small review study and meta-analysis. Still, the study highlighted a need for future clinical trials that use more standardized acupuncture approaches, according to the researchers,…

A potential treatment of relapsing-remitting multiple sclerosis (RRMS), arsenic trioxide (ATO) has been patented in the European Union based on findings in preclinical studies. Notice of an intent to grant patent EP18722530, titled “Method for treating relapsing-remitting multiple sclerosis using arsenic trioxide,” was given by the European Patent…

Blocking the activity of a protein called connexin 43 (Cx43) may be an effective strategy to treat multiple sclerosis (MS), according to a recent study in animal models of the disease. A compound called INI-0602, which was designed to inhibit this protein, significantly eased disease severity in mice, including…

Immutep has been cleared to start a Phase 1 clinical trial in the Netherlands to test IMP761, its experimental antibody therapy for autoimmune diseases such as multiple sclerosis (MS), in healthy volunteers. The first-in-human Phase 1 clinical trial seeks to assess the safety and pharmacological properties of IMP761.

Scientists at The University of Texas at Austin (UT Austin) have developed a novel non-opioid compound, called FEM-1689, that is able to reduce pain related to nerve damage in animal models. Neuropathic pain, or pain caused by damage to nerves, is a common symptom of multiple sclerosis (MS)…

A novel compound that can lessen toxic overactivation of nerve cells was found to significantly reduce disease activity and restore lost myelin in two mouse models of multiple sclerosis (MS), a new study reports. Researchers say the compound, ZCAN262, may be a potential new treatment for MS should future…

Noninvasive brain stimulation (NIBS) may offer promise for treating spasticity in multiple sclerosis (MS), but more work is needed to identify the best approach to use for patients, according to a new review study. The studies under review generally indicated that a type of brain stimulation called repetitive…

NeuroScientific Biopharmaceuticals has filed a patent in Australia to protect the use of its lead candidate EmtinB in combination with Teva’s Copaxone (glatiramer acetate injection) as a potential treatment for multiple sclerosis (MS). The patent application (provisional number 2022903564) is based on data from a lab…

Tevogen Bio has announced plans to develop T-cell therapies targeting the Epstein-Barr virus (EBV), a herpes virus known to be a major environmental risk factor for multiple sclerosis (MS). The decision comes on the heels of positive safety data from a proof-of-concept Phase 1 Tevogen trial that…

Aquatic exercise therapy can help to ease fatigue and improve balance in people with multiple sclerosis (MS), without notable side effects, according to a review of published studies. These findings have important implications for MS patients, as fatigue is among the main symptoms of the disease and…